FDA approves nasal drug delivery device for breakthrough treatment of depression19 Mar 2019
Aptar Pharma’s Bidose liquid system is designed for local or systemic delivery of drugs.
Aptar Pharma's Bidose nasal spray device has been approved by the FDA for a breakthrough therapy in the field of depression. This marks the first FDA approval and US launch of a prescription drug using Aptar Pharma’s patented Bidose nasal spray delivery system.
This approval again demonstrates Aptar Pharma’s expertise in developing patient-friendly drug delivery solutions for breakthrough medicines.
Patented Bidose Technology Platform
Aptar Pharma’s Bidose liquid system is designed for local or systemic delivery of drugs. As a robust, primeless, intuitive and easy-to-use device with 360° functionality and precise spray characteristics, the Bidose system provides accurate two-shot nasal drug delivery.
The Aptar Pharma Bidose and Unidose systems offer biotech and pharmaceutical companies effective and reliable intra-nasal delivery platforms for a variety of medicines including potential life-saving treatments and treatments of severe conditions.
This nasal product platform can enhance brand image via an elegant and intuitive design while limiting the volume of drug accessible to patients. The devices can also integrate wireless connectivity technologies.
Accelerated Development Support via Aptar Pharma Services
This breakthrough therapy approval is an example of a Combination Product, and benefited from Aptar Pharma’s Services offering, a comprehensive portfolio of stage-specific packages designed to proactively address regulatory needs to accelerate approval.
Leveraging its extensive value-adding capabilities including lab and analytical services, proven regulatory expertise - with dedicated Regulatory Affairs experts and fast approval data packages - and customized drug delivery solutions, Aptar Pharma’s Services can enable an expedited approval and launch in the competitive pharmaceutical space.
“We are pleased that Aptar Pharma’s Bidose nasal delivery device has been approved by the FDA for this breakthrough therapy in the field of depression,” explained Gael Touya, President, Aptar Pharma. “This project marks close to a 10-year customer collaboration and once again demonstrates Aptar Pharma’s ability to develop and launch complex drug delivery systems worldwide.”
New HCP Kit for automated impurity analysis of biotherapeutics
21 Jun 2019
Ready-to-use immunoassay kit increases analytical output and productivity in bioprocess workflows.Read more
Sanofi and Google to develop new healthcare Innovation Lab
20 Jun 2019
Collaboration aims to change how Sanofi develops new treatments and will focus on to better understand patients and diseases, to increase Sanofi’s operational efficiency, and to improve the experience of Sanofi’s patients and customers.Read more
Catalent to purchase BMS manufacturing facility
19 Jun 2019
Customers to have access to state-of-the-art sterile biologics fill/finish and oral solids manufacturing and packaging platforms.Read more
Inaugural Bio Integrates conference highlights industry's inefficiency in developing products
18 Jun 2019
Industry leaders give voice to issues and trends shaping the biotech sector, including the importance of collaboration.Read more
Colorcon launches Opadry Enteric for use with hydro-alcoholic media
17 Jun 2019
A fully formulated one-step system providing simple preparation and ease-of-use for film coating.Read more
SenzaGen granted its first patent for GARD potency biomarker test
16 Jun 2019
Company can now offer an animal-free test method to quantify the strength of an allergenic effect.Read more
Affordable measles and rubella vaccines using NevoLine manufacturing platform
14 Jun 2019
Univercells' propriety bioproduction platform has already proven success.Read more
Leaf Expression Systems launches first line of Hypertrans research products
13 Jun 2019
Plant-expression deal for difficult to produce proteins, vaccines, metabolites and natural proteins.Read more
Clinical supply milestone reached for triple-negative breast cancer treatment
12 Jun 2019
PhoenixMD and WuXi STA have produced a multikilogram drug supply for PMD-026 under GMP manufacturing practices.Read more
Combining IT and OT software to solve manufacturing’s most frequent challenges
11 Jun 2019
PTC and Rockwell Automation combine technologies to accelerate customers’ digital transformation initiatives.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation